Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Khandan Keyomarsi

Showing results (11-20 of 105) with videos related to

Pageof 11
Sort By:
Cancer Research|October 2, 2023
Distinct Mechanisms of Resistance to CDK4/6 Inhibitors Require Specific Subsequent Treatment Strategies: One Size Does Not Fit AllHannah F Wingate, Khandan Keyomarsi
Oncoscience|July 24, 2018
Leveraging MYC as a therapeutic treatment option for TNBCJason P W Carey, Khandan Keyomarsi
Journal of Cellular Physiology|September 27, 2006
Deregulation of cyclin E meets dysfunction in p53: closing the escape hatch on breast cancerMichelle Craig Barton, Said Akli, Khandan Keyomarsi
Nature Medicine|February 4, 2003
Cyclin E is a more powerful predictor of breast cancer outcome than proliferationKhandan Keyomarsi, Susan L Tucker, Isabelle Bedrosian
Cancer Treatment and Research|April 5, 2011
Biomarkers in neoadjuvant trialsRegina M Fearmonti, Khandan Keyomarsi, Kelly K Hunt
Cancer Research|March 26, 2009
Altered subcellular localization of tumor-specific cyclin E isoforms affects cyclin-dependent kinase 2 complex formation and proteasomal regulationNikki A Delk, Kelly K Hunt, Khandan Keyomarsi
Cell Cycle (Georgetown, Tex.)|September 10, 2003
The low molecular weight (LMW) isoforms of cyclin E deregulate the cell cycle of mammary epithelial cellsHannah Wingate, Isabelle Bedrosian, Said Akli, et al.
Cell Biology and Toxicology|September 21, 2010
Semi-high throughput method of measuring proteasome inhibition in vitro and in cultured cellsKhandan Keyomarsi, Ekem T Efuet, Tuyen N Bui
Cancer Research|September 9, 2010
The neutrophil elastase inhibitor elafin triggers rb-mediated growth arrest and caspase-dependent apoptosis in breast cancerJoseph A Caruso, Kelly K Hunt, Khandan Keyomarsi
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 19, 2020
Selective CDK4/6 Inhibitors: Biologic Outcomes, Determinants of Sensitivity, Mechanisms of Resistance, Combinatorial Approaches, and Pharmacodynamic BiomarkersErik S Knudsen, Geoffrey I Shapiro, Khandan Keyomarsi
Pageof 11

Showing results (11-20 of 105) with videos related to

Sort By:
Pageof 11
Cancer Research|October 2, 2023
Distinct Mechanisms of Resistance to CDK4/6 Inhibitors Require Specific Subsequent Treatment Strategies: One Size Does Not Fit AllHannah F Wingate, Khandan Keyomarsi
Oncoscience|July 24, 2018
Leveraging MYC as a therapeutic treatment option for TNBCJason P W Carey, Khandan Keyomarsi
Journal of Cellular Physiology|September 27, 2006
Deregulation of cyclin E meets dysfunction in p53: closing the escape hatch on breast cancerMichelle Craig Barton, Said Akli, Khandan Keyomarsi
Nature Medicine|February 4, 2003
Cyclin E is a more powerful predictor of breast cancer outcome than proliferationKhandan Keyomarsi, Susan L Tucker, Isabelle Bedrosian
Cancer Treatment and Research|April 5, 2011
Biomarkers in neoadjuvant trialsRegina M Fearmonti, Khandan Keyomarsi, Kelly K Hunt
Cancer Research|March 26, 2009
Altered subcellular localization of tumor-specific cyclin E isoforms affects cyclin-dependent kinase 2 complex formation and proteasomal regulationNikki A Delk, Kelly K Hunt, Khandan Keyomarsi
Cell Cycle (Georgetown, Tex.)|September 10, 2003
The low molecular weight (LMW) isoforms of cyclin E deregulate the cell cycle of mammary epithelial cellsHannah Wingate, Isabelle Bedrosian, Said Akli, et al.
Cell Biology and Toxicology|September 21, 2010
Semi-high throughput method of measuring proteasome inhibition in vitro and in cultured cellsKhandan Keyomarsi, Ekem T Efuet, Tuyen N Bui
Cancer Research|September 9, 2010
The neutrophil elastase inhibitor elafin triggers rb-mediated growth arrest and caspase-dependent apoptosis in breast cancerJoseph A Caruso, Kelly K Hunt, Khandan Keyomarsi
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 19, 2020
Selective CDK4/6 Inhibitors: Biologic Outcomes, Determinants of Sensitivity, Mechanisms of Resistance, Combinatorial Approaches, and Pharmacodynamic BiomarkersErik S Knudsen, Geoffrey I Shapiro, Khandan Keyomarsi
Pageof 11